24 August 2020: Articles
Unusual clinical course, Rare coexistence of disease or pathologySzeya Cheung A* , Alain Delgado Fuentes F , Alan D. Fetterman E
Am J Case Rep 2020; 21:e927076
BACKGROUND: The novel COVID-19 disease has infected more than 2 million people worldwide, causing more than 120 000 deaths. While the disease is known to primarily affect the respiratory system, gastrointestinal manifestations can also occur. However, little is known about the development of acute pancreatitis in COVID-19. The present report highlights a patient with no precipitating risk factors for pancreatitis who presented with recurring acute pancreatitis following the diagnosis of SARS-CoV-2 infection.
CASE REPORT: An otherwise healthy 38-year-old man presented to the Emergency Department (ED) with fever and epigastric pain. Laboratory testing revealed a lipase level of 10 255 ukat/L. An abdominal ultrasound showed no gallstones. After ruling out the possible causes of acute pancreatitis, a diagnosis of idiopathic acute pancreatitis was made. He received conservative management and was discharged home after being medically stabilized. Of note, the patient tested positive for SARS-CoV-2 infection at a local testing center 1 week prior to presenting to the ED. One week following the discharge, the patient returned with recurrent severe epigastric pain. Laboratory testing showed a lipase level of 20 320 ukat/L. An abdominal CT revealed acute pancreatitis. Further workups, including abdominal ultrasound, hepatitis serology, and immunoglobulin G for autoimmune pancreatitis, were unrevealing. Repeated SARS-CoV-2 testing produced positive results.
CONCLUSIONS: The temporal relationship between clinical presentation of acute pancreatitis and SARS-CoV-2 infection in this patient with no precipitating risk factors for pancreatitis suggests COVID-19-associated acute pancreatitis. Our review of the literature found a handful of reported cases of acute pancreatitis in patients with coexisting SARS-CoV-2 infection, and this report presents the first presumptive case of COVID-19-associated recurring acute pancreatitis.
Keywords: Coronavirus Infections, COVID-19, Pancreatic Diseases, Adult, Betacoronavirus, COVID-19, Cholangiopancreatography, Magnetic Resonance, Male, Pancreatitis, Pandemics, Pneumonia, Viral, Recurrence, SARS-CoV-2, Tomography, X-Ray Computed
The novel coronavirus disease-19 (COVID-19) is a highly infectious disease that was first discovered in Wuhan, China, in December 2019, and has since spread throughout the world, causing a global threat and resulting in more than 120 000 deaths . The disease is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a single-stranded RNA virus that is known to cause respiratory symptoms such as cough and shortness of breath. Gastrointestinal symptoms are relatively uncommon but occur in a subset of patients with COVID-19 infection . However, little is known about the prevalence and the development of acute pancreatitis as a complication of COVID-19. In this report, we describe a case of recurring acute pancreatitis in a patient with recent SARS-CoV-2 infection.
A previously healthy 38-year-old man with positive SARSCoV-2 testing at a local testing center 1 week prior to presentation presented to the Emergency Department (ED) with fever, severe epigastric pain, nausea, and vomiting. He denied similar symptoms in the past. He denied respiratory symptoms, hematemesis, or diarrhea. He had no medical history, and his surgical and social history was noncontributory. Initial laboratory testing was significant for a white blood cell count of 12.53×109L and lipase level of 10 255 ukat/L. The rest of the laboratory study, including calcium, triglyceride, bilirubin, and liver function test, was within normal limits. An abdominal ultrasound showed no cholelithiasis or acute cholecystitis and no biliary dilatation. The patient was admitted for acute pancreatitis of unclear etiology and was placed on airborne and droplet isolation due to his recent outpatient diagnosis of SARS-CoV-2 infection. The patient received conservative management with aggressive intravenous (IV) fluid and pain control. He was discharged after clinical improvement and was instructed to self-isolate at home.
One week following the discharge, the patient returned to the ED complaining of recurrent sharp epigastric pain radiating to the back, associated with nausea and vomiting. He denied fever, cough, or relation of pain to food intake, and he denied alcohol or medication use, recent trauma, or surgery. The patient was placed on airborne isolation after a review of medical records indicated that he had recently tested positive for SARS-CoV-2 infection. Initial vital signs were normal. A physical examination revealed moderate tenderness to light palpation in the epigastric region, and Murphy’s sign was negative. Laboratory testing showed a white blood cell count of 14.82×109L and a lipase level of 20 320 ukat/L. The rest of the laboratory study, including calcium, triglyceride, bilirubin levels, and liver function test, was unremarkable. An abdominal ultra-sound showed a normal gallbladder, no gallstones, and no biliary ductal dilation. A CT of the abdomen revealed acute pancreatitis and no evidence of chronic pancreatitis. The patient was admitted for recurrent idiopathic acute pancreatitis and had received conservative management with IV fluid, complete bowel rest, and pain control. Repeated testing for SARS-CoV-2 viral nucleic acid with a nasopharyngeal specimen using the Roche fully automated COBAS® 6800/8800 System authorized by the Food and Drug Administration (FDA) produced positive results. Further workups with magnetic resonance cholangiopancreatography (MRCP) and magnetic resonance imaging (MRI) of the abdomen showed evidence of acute pancreatitis, normal gallbladder, and no evidence of intra- or extrahepatic biliary pathology. Hepatitis serology and serum immunoglobulin testing for autoimmune pancreatitis was unremarkable. The patient was discharged home after being clinically stabilized and was instructed to return if his symptoms reoccurred.
Complications from SARS-CoV-2 infection are becoming increasing recognized. The virus can cause pneumonia, and can also cause damage to other organ systems, including the gastrointestinal tract; therefore, patients with SARS-CoV-2 infection should not be overlooked, even in the absence of respiratory symptoms. An increase in pancreatic enzymes has been increasingly reported in patients with SARS-CoV-2 infection [3,4]. Our review of the literature showed a few case studies that described the presentation of idiopathic acute pancreatitis in patients with concurrent SARS-CoV-2 infection [5–10]. For example, the presence of severe idiopathic acute pancreatitis was reported in 2 first-degree relatives admitted to the Intensive Care Unit with SARS-CoV-2 infection, and findings suggest that there is a casual association between idiopathic acute pancreatitis and COVID-19 [5,10]. It is also important to note that while respiratory symptoms improve in patients with COVID-19 infection, these patients can still test positive for SARS-CoV-2 and are at risk for developing acute pancreatitis.
Acute pancreatitis is an acute inflammatory process of the pancreas, with a potential for significant morbidity. The diagnosis of acute pancreatitis requires 2 of the following 3 criteria: 1) characteristic acute epigastric pain; 2) elevation of serum amylase or lipase more than 3 times the upper limit of normal; and 3) evidence of acute pancreatitis on diagnostic imaging . Gallstones and alcohol use are the 2 most common etiologies and account for more than 80% of all cases of acute pancreatitis. Other causes of acute pancreatitis include hypertriglyceridemia, hypercalcemia, medications, and trauma . Viral pancreatitis was also been reported in the literature, with the most common viral agents being mumps, measles, hepatitis A/B, Epstein-Barr virus, and Coxsackie virus. Clues to the infectious nature of pancreatitis lay in the characteristic signs and symptoms associated with the particular infectious agent .
The finding of an association between idiopathic pancreatitis and COVID-19 is interesting, but little is known about the prevalence and the pathogenesis of acute pancreatitis in SARSCoV-2 infection [3,4]. It is thought that angiotensin-converting enzyme 2 receptors (ACE-2) can play a role in the pathogenesis of COVID-19, and these transmembrane proteins are highly expressed in pancreatic cells. However, it is also unclear whether COVID-19-related acute pancreatitis is due to the direct cytopathic effect of local viral replications or indirectly by a harmful immune response generated by the virus [4,5,9]. The recent diagnosis of COVID-19 and the presentation of recurring acute pancreatitis in this patient with no known precipitating factors of pancreatitis raise the suspicion that there is a causal relationship between this novel virus and acute pancreatitis.
It is important to consider SARS-CoV-2 as a new etiology of acute pancreatitis, and cases of idiopathic pancreatitis warrant further testing for SARS-CoV-2 infection given association of idiopathic pancreatic with COVID-19. Pancreatic enzymes can also be evaluated in COVID-19 patients who present with gastrointestinal symptoms to rule out probable unrecognized pancreatic involvement in this population.
1.. : Coronavirus disease (COVID-19) Pandemic June 13, 2020, Geneva, World Health Organization http://www.who.int/emergencies/diseases/novel-coronavirus-2019
2.. Cheung KS, Hung IFN, Chan PPY: Gastroenterology, 2020; 159(1); 81-95
3.. Wang F, Wang H, Fan J: Gastroenterology, 2020; 159(1); 367-70
4.. Liu F, Long X, Zhang B: Clin Gastroenterol Hepatol, 2020; 18(9); 2128-30.e2
5.. Hadi A, Werge M, Kristiansen KT: Pancreatology, 2020; 20(4); 665-67
6.. Alloway BC, Yaeger SK, Mazzaccaro RJ: Radiol Case Rep, 2020; 15(8); 1309-12
7.. Rabice SR, Altshuler PC, Bovet C: Case Rep Womens Health, 2020; 27; e00228
8.. Mazrouei SSA, Saeed GA, Hilali A: Radiol Case Rep, 2020; 15(9); 1601-3
9.. Aloysius MM, Thatti A, Gupta A: Pancreatology, 2020; 20(5); 1026-27
10.. Gubatan J, Levitte S, Patel A: Gut, 2020 [Online ahead of print]
11.. Yang AL, Vadhavkar S, Singh G: Arch Intern Med, 2008; 168(6); 649-56
12.. Parenti DM, Steinberg W, Kang P: Pancreas, 1996; 13(4); 356-71
19 May 2022 : Case reportBilateral Emphysematous Pyelonephritis Associated with COVID Pneumonia: A Case Report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case reportHigh-Frequency Oscillatory Ventilation for Refractory Hypoxemia in Severe COVID-19 Pneumonia: A Small Case ...
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case reportA case of exacerbation of haloperidol-induced rhabdomyolysis following the onset of COVID-19
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
20 May 2022 : Case reportDiagnostic Puzzle of Acute Ischemic Stroke Mimics – Seizure Versus Post-Stroke Recrudescence: A Case Report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
19 May 2022 : Case reportExtremes of Anemia: The Lowest Hemoglobin Values Probably Ever Reported in the Pediatric Literature Attribu...
Am J Case Rep In Press; DOI: 10.12659/AJCR.936252
19 May 2022 : Case reportAcute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury
Am J Case Rep In Press; DOI: 10.12659/AJCR.936318
Most Viewed Current Articles
31 Dec 1969 : Case reportPenile Necrosis Associated with Local Intravenous Injection of Cocaine
Am J Case Rep 2022; 23:e935250
31 Dec 1969 : Case reportMyocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...
Am J Case Rep 2022; 23:e934399
31 Dec 1969 : Case reportLipedema Can Be Treated Non-Surgically: A Report of 5 Cases
Am J Case Rep 2021; 22:e934406